Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnevist intra-individual dose comparison in metastatic brain tumor
NCT00681551Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of gadopentetate dimeglumine in brain tumor, sponsored by Bayer. Primary endpoint: Diagnostic ability. Started Feb 2003; status: completed.
02
Drugs
gadopentetate dimeglumine
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT00681551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681551.